MABp1 has been evaluated for the treatment of psoriasis (Coleman et al., 2015), acne vulgaris (Carrasco et al., 2015), T2DM (Timper et al., 2015) and is currently being evaluated in patients with hidradenitis suppurativa (HS) who were refractory to anti-TNFα treatment (discussed below). This evidence concerns the gene TNF and histiocytic sarcoma.